Adegoke Adeniji, Ph.D.
Affiliations: | 2010 | University of the Sciences in Philadelphia |
Area:
Pharmacology, Pharmaceutical ChemistryGoogle:
"Adegoke Adeniji"Mean distance: (not calculated yet)
Parents
Sign in to add mentor| Adeboye Adejare | grad student | 2010 | University of the Sciences in Philadelphia | |
| (Structure activity relationship (SAR) studies of a novel gamma-secretase inhibitor.) | ||||
| Trevor M. Penning | post-doc | Penn | ||
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Wangtrakuldee P, Adeniji AO, Zang T, et al. (2019) A 3-(4-Nitronaphthen-1-yl) amino-benzoate analog as a Bifunctional AKR1C3 Inhibitor with AR Antagonist Activity: Head to Head Comparison with Other Advanced AKR1C3 Targeted Therapeutics. The Journal of Steroid Biochemistry and Molecular Biology |
| Adeniji AO, Uddin MJ, Zang T, et al. (2016) Discovery of (R)-2-(6-methoxynaphthalen-2-yl)butanoic acid As a Potent and Selective Aldo-keto Reductase 1C3 Inhibitor. Journal of Medicinal Chemistry |
| Adeniji AO, Chen M, Penning TM. (2013) AKR1C3 as a target in castrate resistant prostate cancer. The Journal of Steroid Biochemistry and Molecular Biology. 137: 136-49 |
| Liedtke AJ, Adeniji AO, Chen M, et al. (2013) Development of potent and selective indomethacin analogues for the inhibition of AKR1C3 (Type 5 17β-hydroxysteroid dehydrogenase/prostaglandin F synthase) in castrate-resistant prostate cancer. Journal of Medicinal Chemistry. 56: 2429-46 |
| Sinreih M, Sosič I, Beranič N, et al. (2012) N-Benzoyl anthranilic acid derivatives as selective inhibitors of aldo-keto reductase AKR1C3. Bioorganic & Medicinal Chemistry Letters. 22: 5948-51 |
| Brožič P, Turk S, Adeniji AO, et al. (2012) Selective inhibitors of aldo-keto reductases AKR1C1 and AKR1C3 discovered by virtual screening of a fragment library. Journal of Medicinal Chemistry. 55: 7417-24 |
| Chen M, Adeniji AO, Twenter BM, et al. (2012) Crystal structures of AKR1C3 containing an N-(aryl)amino-benzoate inhibitor and a bifunctional AKR1C3 inhibitor and androgen receptor antagonist. Therapeutic leads for castrate resistant prostate cancer. Bioorganic & Medicinal Chemistry Letters. 22: 3492-7 |
| Adeniji AO, Wells RM, Adejare A. (2012) Syntheses and in-vitro evaluation of novel adamantane based γ-secretase inhibitors. Current Medicinal Chemistry. 19: 2458-71 |
| Adeniji AO, Twenter BM, Byrns MC, et al. (2012) Development of potent and selective inhibitors of aldo-keto reductase 1C3 (type 5 17β-hydroxysteroid dehydrogenase) based on N-phenyl-aminobenzoates and their structure-activity relationships. Journal of Medicinal Chemistry. 55: 2311-23 |
| Adeniji A, Liedkte A, Byrns MC, et al. (2012) Abstract B16: Development of potent and selective indomethacin analogs for the inhibition of AKR1C3 (type 5 17 -hydroxysteroid dehydrogenase) in CRPC Cancer Research. 72: B16-B16 |